, к дневно при приблизително 20 000 пациенти с нестабилна стенокардия/ миокарден инфаркт без
ra OASIS 5 was a double-blind, randomised, non-inferiority study with fondaparinux 2.5 mg subcutaneously once daily versus enoxaparin 1 mg/ kg subcutaneously twice daily in approximately 20,000 patients with UA/ NSTEMI.